USFDA grants Orphan Drug Designation (ODD) to Zydus’ Desidustat for treatment of beta-thalassemia EP News Bureau Nov 6, 2025 Zydus, a leading, discovery-based, global pharmaceutical company announced that the USFDA has granted Orphan Drug Designation…
Regrow Biosciences gets US FDA nod for phase-II trials of Ossgrow for Osteonecrosis in US EP News Bureau May 23, 2022 The company moves one-step closer to attain a global market monopoly estimated at $5 billion through this feat
US FDA grants Orphan Drug Designation to BCMA CAR-T cell therapy co-developed by Innovent Biologics… EP News Bureau Feb 15, 2022 ODD will accelerate drug development and registration action in the US
